Retrospective Cohort Study
Copyright ©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Feb 14, 2021; 27(6): 501-512
Published online Feb 14, 2021. doi: 10.3748/wjg.v27.i6.501
Validation of serum tumor biomarkers in predicting advanced cystic mucinous neoplasm of the pancreas
Li-Qi Sun, Li-Si Peng, Jie-Fang Guo, Fei Jiang, Fang Cui, Hao-Jie Huang, Zhen-Dong Jin
Li-Qi Sun, Li-Si Peng, Jie-Fang Guo, Fei Jiang, Fang Cui, Hao-Jie Huang, Zhen-Dong Jin, Department of Gastroenterology, Changhai Hospital, Second Military Medical University, Shanghai 200433, China
Author contributions: Sun LQ, Peng LS, and Guo JF contributed equally to this study and should be regarded as co-first authors; Sun LQ, Peng LS, and Guo JF were responsible for study design/planning, study conduct, data analysis, and writing and revising the paper; Jiang F and Cui F assisted with data collection and analysis; Jin ZD and Huang HJ designed the study and they shared co-corresponding authorship; all authors have read and approved the final manuscript.
Supported by National Natural Science Foundation of China, No. 81770642; the Shanghai Association for Science and Technology, China, No. 19411951602.
Institutional review board statement: The study was reviewed and approved by the Shanghai Changhai Hospital Ethics Committee (CHEC No. 2019-081).
Conflict-of-interest statement: The authors declare no conflicts of interest.
Data sharing statement: No additional data are available.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Zhen-Dong Jin, MD, PhD, Director, Professor, Department of Gastroenterology, Changhai Hospital, Second Military Medical University, No. 168 Changhai Road, Yangpu District, Shanghai 200433, China. zhendongjin@163.com
Received: December 12, 2020
Peer-review started: December 12, 2020
First decision: December 17, 2020
Revised: December 30, 2020
Accepted: January 12, 2021
Article in press: January 12, 2021
Published online: February 14, 2021
Core Tip

Core Tip: The value of serum tumor markers (STMs) in predicting advanced cystic mucinous neoplasms (A-cMNs) has not been well studied except for carbohydrate antigen (CA) 19-9. Our study illustrates for the first time the potential value of multiple STMs in the diagnosis of A-cMNs. CA19-9 was the most accurate STM in predicting A-cMNs with a moderate ability. CEA, CA125, and CA724 showed a low ability to predict A-cMNs. CA125 may be specific to the diagnosis of advanced mucinous cystic neoplasms. CA242 was not identified as a useful STM in predicting A-cMNs in our study. The combination of STMs could improve sensitivity in predicting A-cMNs.